Clinical and Molecular Characteristics of Patients with Bloodstream Infections Caused by KPC and NDM Co-Producing Carbapenem-Resistant Klebsiella pneumoniae

Jiayang Li,Wenqi Wu,Meilin Wu,Zhitao Zhou,Jiajie Wang,Mingjie Qiu,Li Xu,Jianan Ren,Xiuwen Wu

DOI: https://doi.org/10.2147/idr.s455146

2024-05-02

Infection and Drug Resistance

Abstract:Jiayang Li, 1, 2, &ast Wenqi Wu, 3, &ast Meilin Wu, 4 Zhitao Zhou, 4 Jiajie Wang, 1 Mingjie Qiu, 4 Li Xu, 4 Jianan Ren, 1, 2 Xiuwen Wu 1, 2 1 School of Medicine, Southeast University, Nanjing, People's Republic of China; 2 Research Institute of General Surgery, Jinling Hospital, School of Medicine, Southeast University, Nanjing, People's Republic of China; 3 School of Medicine, Nanjing University, Nanjing, People's Republic of China; 4 Nanjing Medical University, Nanjing, People's Republic of China &astThese authors contributed equally to this work Correspondence: Xiuwen Wu; Jianan Ren, Research Institute of General Surgery, Jinling Hospital, School of Medicine, Southeast University, 305 East Zhongshan Road, Nanjing, 210002, People's Republic of China, Email ; Purpose: Klebsiella pneumoniae carbapenemase (KPC) and New Delhi metallo-β-lactamase (NDM) co-producing carbapenem-resistant Klebsiella pneumoniae (KPC-NDM-CRKP) isolates have been increasingly reported worldwide but have not yet been systematically studied. Thus, we have conducted a study to compare the risk factors, molecular characteristics, and mortality involved in clinical bloodstream infections (BSIs) caused by KPC-NDM-CRKP and KPC-CRKP strains. Methods: A retrospective study was conducted on 231 patients with BSIs caused by CRKP at Jinling Hospital in China from January 2020 to December 2022. Antimicrobial susceptibility testing, carbapenemase genes detection and whole-genome sequencing were performed subsequently. Results: Overall, 231 patients were included in this study: 25 patients with KPC-NDM-CRKP BSIs and 206 patients with KPC-CRKP BSIs. Multivariate analysis implicated ICU-acquired BSI, surgery within 30 days, and longer stay of hospitalization prior to CRKP isolation as independent risk factors for KPC-NDM-CRKP BSIs. The 30-day mortality rate of the KPC-NDM-CRKP BSIs group was 56% (14/25) compared with 32.5% (67/206) in the KPC-CRKP BSIs control group ( P = 0.02). The ICU-acquired BSIs, APACHE II score at BSI onset, and BSIs caused by KPC-NDM-CRKP were independent predictors for 30-day mortality in patients with CRKP bacteremia. The most prevalent ST in KPC-NDM-CRKP isolates was ST11 (23/25, 92%), followed by ST15 (2/25, 8%). Conclusion: In patients with CRKP BSIs, KPC-NDM-CRKP was associated with an excess of mortality. The likelihood that KPC-NDM-CRKP will become the next "superbug" highlights the significance of epidemiologic surveillance and clinical awareness of this pathogen. Keywords: KPC and NDM co-producing carbapenem-resistant Klebsiella pneumoniae , Bloodstream infections, risk factors, molecular characteristics, mortality Carbapenem-resistant Klebsiella pneumoniae (CRKP) represents a catastrophic threat to global public health and clinical settings due to the presence of mobile carbapenemases. Klebsiella pneumoniae carbapenemase (KPC, class A) and New Delhi metallo-β-lactamase (NDM, class B) are two of the more prevalently encountered carbapenemases worldwide. 1,2 Recently, KPC and NDM co-producing K. pneumoniae (KPC-NDM-CRKP) isolates have been increasingly reported in China and many regions of the world. 3,4 KPC and NDM belong to different carbapenemase classes. The infection caused by KPC-producing organisms has been partially solved by the introduction of newer β-lactamase inhibitors, such as avibactam, relebactam, and vaborbactam. This solution is limited because these newer β-lactamase inhibitors could not cover NDM. In addition, NDM is able to hydrolyze all β-lactams except monobactams, while KPC can also deactivate monobactams. 5–7 Thus, the emergence of KPC-NDM-CRKPs results in higher level of antimicrobial resistance and extremely limited treatment options, which may further lead to increased mortality rates. 3,8 However, several studies have been conducted on risk factors and clinical outcomes for CRKP bloodstream infections (BSIs). 9 The results of risk factors are highly heterogeneous, and deaths attributable to CRKP BSIs vary from 20% to 45%. 10,11 To the best of our knowledge, no studies have focused on BSIs caused by KPC-NDM-CRKPs. The identification of risk factors and mortality of infections caused by KPC-NDM-CRKPs is important to highlight the significance of epidemiologic surveillance and clinical awareness of this pathogen. Thus, we have conducted a study to compare the risk factors, molecular characteristics, and mortality involved in clinical BSIs caused by KPC-NDM-CRKP and KPC-CRKP strains. The st -Abstract Truncated-

pharmacology & pharmacy,infectious diseases